NO20032613L - Farmasöytisk sammensetning som har forbedret vannlöselighet - Google Patents

Farmasöytisk sammensetning som har forbedret vannlöselighet

Info

Publication number
NO20032613L
NO20032613L NO20032613A NO20032613A NO20032613L NO 20032613 L NO20032613 L NO 20032613L NO 20032613 A NO20032613 A NO 20032613A NO 20032613 A NO20032613 A NO 20032613A NO 20032613 L NO20032613 L NO 20032613L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
water solubility
improved water
improved
solubility
Prior art date
Application number
NO20032613A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032613D0 (no
Inventor
Yohko Akiyama
Satoshi Iinuma
Hiroto Bando
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO20032613D0 publication Critical patent/NO20032613D0/no
Publication of NO20032613L publication Critical patent/NO20032613L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20032613A 2000-12-11 2003-06-10 Farmasöytisk sammensetning som har forbedret vannlöselighet NO20032613L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000375601 2000-12-11
PCT/JP2001/010768 WO2002048141A1 (fr) 2000-12-11 2001-12-10 Composition medicinale dont la solubilite dans l'eau est amelioree

Publications (2)

Publication Number Publication Date
NO20032613D0 NO20032613D0 (no) 2003-06-10
NO20032613L true NO20032613L (no) 2003-08-05

Family

ID=18844590

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032613A NO20032613L (no) 2000-12-11 2003-06-10 Farmasöytisk sammensetning som har forbedret vannlöselighet

Country Status (10)

Country Link
US (1) US20040058956A1 (pl)
EP (1) EP1350792A1 (pl)
KR (1) KR20040025880A (pl)
CN (1) CN1487935A (pl)
AU (1) AU2002221096A1 (pl)
CA (1) CA2431319A1 (pl)
HU (1) HUP0401811A2 (pl)
NO (1) NO20032613L (pl)
PL (1) PL362979A1 (pl)
WO (1) WO2002048141A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
EP1439178A4 (en) * 2001-10-05 2005-11-16 Takeda Pharmaceutical Heterocyclic compounds, oxazole derivatives, process for their preparation and their use
EP1479666A4 (en) 2002-02-28 2010-10-13 Japan Tobacco Inc ESTER CONNECTION AND THEIR MEDICAL USE
MY147403A (en) * 2003-04-29 2012-11-30 Kowa Co Composition containing medicine extremely slightly solube in water and method for preparation thereof
JP4579825B2 (ja) * 2003-04-29 2010-11-10 興和株式会社 溶出性に優れた超難水溶性薬物含有組成物及びその製造法
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
KR20070072888A (ko) * 2004-10-25 2007-07-06 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
MX2007005361A (es) * 2004-11-05 2008-01-11 Cephalon Inc Tratamientos para cancer.
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
EP1902732A4 (en) * 2005-06-24 2009-07-22 Takeda Pharmaceutical PROPHYLACTIC / THERAPEUTIC AGENT AGAINST HER2-EXPRESSIVE CANCER
JP2009509998A (ja) * 2005-09-30 2009-03-12 エフ.ホフマン−ラ ロシュ アーゲー ジアジンアゾール誘導体、それらの製造及び薬剤としての使用
KR100767349B1 (ko) * 2006-08-01 2007-10-17 삼천당제약주식회사 페노피브레이트를 함유하는 경구용 약제 조성물 및 그의제조방법
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CA2735899A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
US8076366B2 (en) * 2009-01-15 2011-12-13 Cephalon, Inc. Forms of bendamustine free base
CN103153306A (zh) * 2010-05-31 2013-06-12 安斯泰来制药有限公司 三唑化合物的固体分散体
NZ610638A (en) 2010-11-24 2015-05-29 Melinta Therapeutics Inc Pharmaceutical compositions comprising radezolid
WO2013056108A2 (en) * 2011-10-14 2013-04-18 Array Biopharma Inc. Solid dispersion
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
AU2014233363B2 (en) * 2013-03-15 2017-06-29 EyePoint, Inc. Compositions, formulations and methods for treating ocular diseases
CN106232144B (zh) * 2014-03-18 2019-12-06 武田药品工业株式会社 固体分散体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5352617A (en) * 1976-10-25 1978-05-13 Shin Etsu Chem Co Ltd Solid drug coating composition
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
AU4314196A (en) * 1994-12-21 1996-07-10 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
DE122007000079I2 (de) * 1996-07-24 2010-08-12 Celgene Corp Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
WO1998051281A1 (en) * 1997-05-14 1998-11-19 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility

Also Published As

Publication number Publication date
WO2002048141A1 (fr) 2002-06-20
HUP0401811A2 (hu) 2004-12-28
AU2002221096A1 (en) 2002-06-24
NO20032613D0 (no) 2003-06-10
US20040058956A1 (en) 2004-03-25
EP1350792A1 (en) 2003-10-08
CN1487935A (zh) 2004-04-07
KR20040025880A (ko) 2004-03-26
PL362979A1 (pl) 2004-11-02
CA2431319A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
NO20032613L (no) Farmasöytisk sammensetning som har forbedret vannlöselighet
ITTO20000779A0 (it) Composizioni farmaceutiche.
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
NO20030153D0 (no) Blandinger som inneholder terapeutisk aktive komponenter som har foröket löselighet
ITMI20010748A0 (it) Composizioni farmaceutiche
DE50104135D1 (de) Wässrige zusammensetzungen
NO20026195D0 (no) Substituerte-triazolopyrimidiner som anticancer midler
ATE303787T1 (de) Schergelzusammensetzungen
NO20052306D0 (no) Dispergerbare farmasoytiske blandinger.
AR028197A1 (es) Composiciones antitranspirantes
DK1592457T3 (da) Folat-vinblastin-konjugat som lægemiddel
ITTO20010005A1 (it) Formulazione farmaceutica.
DK1524266T3 (da) Farmaceutisk sammensætning
NO20026175L (no) Vaksinesammensetning
PL375874A1 (pl) Wodne kompozycje farmaceutyczne 2,6-diizopropylofenolu
MXPA03001425A (es) Compuestos farmaceuticos.
EE200300589A (et) Ravimkoostised
NO20026123L (no) Farmasöytiske sammensetninger
ATE369830T1 (de) Schweisshemmende zusammensetzungen
ATE314049T1 (de) Schweisshemmende zusammensetzungen
NO20040860L (no) Farmasoytisk sammensetning som innbefatter lumiracoxib
NO20032614L (no) Farmasöytisk sammensetning som har forbedret absorberbarhet
NO20031095L (no) Farmasoytiske sammensetninger
ATE266316T1 (de) Fungizide zusammensetzungen
NO20013441D0 (no) Sammensetninger som har forbedret stabilitet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application